GlassScriptPhysician profile
Nikki Rubinstein
NPI 1114482056
$2,913.62
in general payments reported to CMS, 2019-2025
32 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $390 · 2023: $782 · 2024: $1,114 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $473.21 | 2022-2025 | |
| Novo Nordisk INC | $360.29 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $318.39 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.68 | 2022-2024 | |
| Astellas Pharma US INC | $214.03 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $201.80 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Baxter Healthcare | $136.76 | 2025 | Adept, Tisseel, Floseal |
| Glaxosmithkline, LLC. | $103.57 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $92.71 | 2022-2024 | Prolia, Evenity, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.27 | 2023-2025 | Xifaxan |
| Exact Sciences Corporation | $68.50 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $68.24 | 2023-2024 | Korlym |
| Merck Sharp & Dohme LLC | $62.88 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $58.99 | 2022-2024 | Airsupra, Breztri |
| Dexcom, INC. | $43.74 | 2024 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $42.40 | 2022 | |
| Phadia US INC. | $38.64 | 2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.90 | 2022-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $36.52 | 2023-2024 | Quviviq |
| Mvp Orthopedics INC | $28.88 | 2023 | |
| Daiichi Sankyo INC. | $27.02 | 2023 | Injectafer |
| Lundbeck LLC | $22.82 | 2025 | Vyepti |
| Lucid Diagnostics INC. | $22.23 | 2022 | |
| Si-Bone, INC. | $19.61 | 2023 | |
| Tris Pharma INC | $19.16 | 2024 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.02 | 2025 | Caplyta |
| Vbi Vaccine (Delaware) INC. | $19.00 | 2022 | |
| Nevro Corp. | $17.60 | 2023 | Senza |
| Halozyme INC | $15.41 | 2023 | |
| Antares Pharma, INC. | $14.68 | 2024 | Xyosted |
| Sumitomo Pharma America, INC. | $14.66 | 2025 | Myfembree |
| Biohaven Pharmaceutical Holding Company LTD. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikki Rubinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.